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RNAi is widely appreciated as a powerful regulator of
mRNA translation in the cytoplasm of mammalian
cells. However, the presence and activity of RNAi
factors in the mammalian nucleus has been the sub-
ject of considerable debate. Here, we show that
Argonaute-2 (Ago2) and RNAi factors Dicer, TRBP,
and TRNC6A/GW182 are in the human nucleus and
associate together in multiprotein complexes. Small
RNAs can silence nuclear RNA and guide site-
specific cleavage of the targeted RNA, demon-
strating that RNAi can function in the human nucleus.
Nuclear Dicer is active and miRNAs are bound to nu-
clear Ago2, consistent with the existence of nuclear
miRNA pathways. Notably, we do not detect loading
of duplex small RNAs in nuclear extracts and known
loading factors are absent. These results extend
RNAi into the mammalian nucleus and suggest that
regulation of RNAi via small RNA loading of Ago2 dif-
fers between the cytoplasm and the nucleus.INTRODUCTION
Since the discovery of mammalian RNAi (Elbashir et al., 2001),
over 50,000 reports have described the use of small interfering
RNAs (siRNAs). Almost all of these studies have assumed that
the regulation of RNAi and its silencing activity occurs in the
cytoplasm (Gurtan and Sharp, 2013). Whether RNAi can function
in the mammalian nucleus and regulate processes like transcrip-
tion or splicing has remained unclear (Castel and Martienssen,
2013; Harel-Bellan et al., 2013). Likewise, what role the nuclear
compartment might play in the regulation of RNAi pathways is
unknown. These uncertainties have significantly hampered
investigation of nuclear RNA biology and the development of nu-
clear RNAi as a laboratory tool and potential therapeutic.
The assumption that mammalian RNAi is confined to the
cytoplasm has been supported by reports that siRNAs cannot
silence introns (Vickers et al., 2003; Zeng and Cullen, 2002). In
addition, microscopy has shown a cytoplasmic distribution of
RNAi factors, such as Argonaute-2 (Ago2), to P-bodies and the
endoplasmic reticulum (ER) (Ikeda et al., 2006; Stalder et al.,C2013). Some laboratories, however, have suggested that Ago2
and other RNAi factors can be found in the nucleus (Ando
et al., 2011; Chu et al., 2010; Doyle et al., 2013; Ohrt et al.,
2012; Ru¨del et al., 2008; Till et al., 2007; Weinmann et al.,
2009). siRNAs have been reported to silence the nuclear
enriched RNAs 7SK and U6 (Ohrt et al., 2008; Robb et al.,
2005). Although nuclear RNAi activity and localization of RNAi
factors to the nucleus have been reported previously, questions
about the purity of cell extracts (Holding, 2004), the resolution of
localization studies, and nucleocytoplasmic transport of the RNA
targets and products of RNAi have kept nuclear RNAi a contro-
versial subject.
MicroRNAs (miRNAs) enter the RNAi pathway by binding Ago
proteins (Gurtan and Sharp, 2013). In the cytoplasm, miRNAs
guide Ago proteins to 30 untranslated regions and destabilize
or inhibit translation of mRNAs (Bartel, 2009; Gurtan and Sharp,
2013; Valencia-Sanchez et al., 2006). miRNAs have also been
found in the nucleus (Jeffries et al., 2011; Katahira and Yoneda,
2011; Liao et al., 2010), but their biological roles are unknown.
Both synthetic siRNAs and microRNAs have been shown to
induce changes in splicing (Allo´ et al., 2009; Liu et al., 2012)
and transcription (Janowski et al., 2007; Li et al., 2006; Matsui
et al., 2013;Morris et al., 2004). However, themechanismsmedi-
ating these processes remain controversial, due in part to the
debate over the presence and activity of nuclear RNAi factors.
During cytoplasmic RNAi, small RNA loads into the RNA
induced silencing complex (RISC), the complex recognizes a
complementary RNA target, and target cleavage can occur at
a specific site (Wilson and Doudna, 2013). Several factors have
been implicated in the loading of small RNAs into Ago proteins
(programming) and thematuration of RISC in human cells. These
include the protein folding chaperones Hsp90 and Hsc70
(Iwasaki et al., 2010) and the component 3 promoter of RNAi
(C3PO) complex composed of Translin and TRAX (Ye et al.,
2011). Hsp90/Hsc70 are implicated in chaperone-like mecha-
nisms that may open Ago proteins to accommodate the initial
binding of a duplex RNA (Iwasaki et al., 2010). In addition,
Hsp90 chaperone activity in RNAi programming and RISCmatu-
ration has been shown to be dependent on the presence of
cochaperones, including Aha1, FKBP4/5, Cdc37, and p23
(Martinez et al., 2013; Pare et al., 2013). C3PO possesses
single-strand nuclease activity and has been shown to accel-
erate passenger strand RNA removal from Ago to mature the
RISC complex (Liu et al., 2009; Ye et al., 2011).ell Reports 6, 211–221, January 16, 2014 ª2014 The Authors 211
Figure 1. Microscopy Reveals Ago2 in Human Cell Nuclei
Immunofluorescence microscopy of endogenous Ago2 in HeLa cells. z
sections are stacked (6 mm), projected three-dimensionally, and rotated to
highlight nuclear staining. Scale bar represents 3 mm.Ago2 binds small duplex RNA and forms the core of RISC
(Hammond et al., 2000; MacRae et al., 2008; Wilson and
Doudna, 2013). Other key players involved in RISC include the
pre-miRNA processing enzyme Dicer, the TAR RNA-binding
protein (TRBP), and TNRC6A (GW182 homolog) (Daniels and
Gatignol, 2012; Lazzaretti et al., 2009; Ma et al., 2012; MacRae
et al., 2008). Ago-RISC complexes recognize RNAs complemen-
tary to the guide strand (Hammond et al., 2000). When the guide
strand is fully complementary to target RNA, Ago2 can catalyze
site-specific phosphodiester bond cleavage (‘‘slicer’’ activity)
(Liu et al., 2004; Meister et al., 2004; Wang et al., 2008).
To resolve the controversy over mammalian nuclear RNAi, we
investigated the localization, interaction, and activity of known
RNAi factors in human cell nuclei. Here, we show that Ago2
and other RNAi factors are present in the nucleus and can asso-
ciate in multiprotein complexes. Small RNAs in complex with
Ago2 can silence nuclear RNA and induce site-specific cleav-
age. Nuclear Dicer is catalytically active and miRNAs are bound
to nuclear Ago2. In contrast, we did not detect loading of duplex
RNA in nuclei and most RISC loading factors are absent. These
results place the protein machinery necessary for RNAi recogni-
tion inside the mammalian cell nucleus but suggest key differ-
ences between nuclear and cytoplasmic RNAi.
RESULTS
RNAi Factors Are Present in Human Cell Nuclei
We began our study by using HeLa cells to examine the localiza-
tion of Ago2, the catalytic core of RNAi (Liu et al., 2004). We used212 Cell Reports 6, 211–221, January 16, 2014 ª2014 The Authorswide-field immunoepifluorescence microscopy with blind
deconvolution because the technique is ideal for rapid and
high-sensitivity 3D imaging for thin specimens such as cells in
monolayer culture (Shaw, 2006). In some cases, we also used
confocal immunofluorescence microscopy for comparison.
The success of immunofluorescence often depends on condi-
tions like fixation and permeabilization, antibody binding, and
cell type (Katikireddy and O’Sullivan, 2011). To improve detec-
tion of nuclear proteins, we used protocols designed to facilitate
entry of antibody into the nucleus (Spector, 2011).
Our microscopy revealed a substantial amount of Ago2 in
the nucleus in addition to the expected distribution within the
cytoplasm. Images of slices through several micrometer thick
sections along the z axis, combined with 3D rendering of
composite focal sections, revealed Ago2 within the nuclear
compartment (Figure 1; Movie S1). The application of two addi-
tional antibodies against human Ago2 produced similar results
(Figures S1A–S1C), confirming that nuclear visualization was
not due to off-target immunoreactivity. We also observed Ago2
in the nuclei of T47D breast cancer cells and fibroblast cells
(Figures S1D–S1F), indicating that nuclear Ago2 is not cell type
specific. Confocal microscopy confirmed nuclear localization
of Ago2 (Figures S1G and S1H). We also used wide-field immu-
nofluorescence microscopy to test localization of Dicer, TRBP,
and TNRC6A and observed staining in the nucleus as well as in
the cytoplasm (Figures S1I–S1K). These results using different
microscopy platforms, cell lines, and detection reagents suggest
the nuclear presence of the protein machinery that enables
RNAi.
As a second method for testing nuclear localization, we
used cellular fractionation and western blot analysis to evaluate
the levels of Ago2 and other RNAi factors in the nucleus. We
developed a stepwise protocol for isolating cytoplasmic,
whole nuclear, nucleoplasmic (soluble nuclear), and chromatin-
associated fractions from the same cell population. Fractions
were used for various assays, including protein and RNA detec-
tion, chromatographic or biochemical fractionation, and enzy-
matic assays (Figure 2A).
RNAi factors can localize to the ER (Stalder et al., 2013). This
poses a challenge for accurate assessment of localization inside
of nuclei because the ERmembrane is contiguous with the outer
nuclear membrane (Hetzer, 2010). To ensure efficient removal of
ER protein contamination, we tested detergents and conditions
for preparation of nuclear extracts (Michelsen and von Hagen,
2009). Nuclei were washed with buffers containing different
detergents and then visualized by fluorescence microscopy
using DAPI and ER tracker, a fluorescent dye that binds the
sulphonylurea receptor class of ER integral membrane proteins.
Our microscopy indicated that the addition of 0.3% NP-40
was most efficient at removing ER contamination (Figure 2B).
Western blots confirmed the absence of both ER lumen and
ER membrane proteins from nuclear extracts (Figure 2C).
Western blot analysis of purified nuclei revealed endogenous
Ago2, Dicer, TRBP, and TRNC6A in the nuclei of multiple human
cell lines (Figure 2D). Protein markers for the cytoplasm, ER, and
mitochondria were absent from nuclear preparations, consistent
with stringent isolation of nuclei. Quantitation of western blots
revealed relative nuclear abundances ranging from 40% to
Figure 2. RNAi Factors Are Present in Nuclear Extracts
(A) Schematic of cellular fractionation protocol.
(B) Fluorescent imaging of intact HeLa nuclei after isolation with buffers con-
taining different detergents. ER membrane is stained yellow with ER Tracker
dye, DAPI staining of nuclei.
(C) Western blot analysis of cytoplasmic and nuclear fractions prepared with
buffers containing different detergents. Calreticulin is a marker for the ER
lumen. Calnexin is a marker for the ER membrane.
(D)Western blot of RNAi factors and subcellular markers from cytoplasmic and
nuclear fractions prepared with 0.3% NP-40. Oxphos is a marker for mitch-
odondria, Lamin A/C is a marker for nuclear matrix, and tubulin is a marker for
cytoplam.
C50% (Figure 2E). We also observed the other human Ago vari-
ants, Ago1, Ago3, and Ago4, in our nuclear preparations (Fig-
ure S2). Combined with microscopy, our analysis of cell fractions
demonstrates that the basic machinery necessary to execute
RNAi is present in human cell nuclei.
Nuclear RNAi Factors Can Stably Associate in
Multiprotein Complexes
RNAi factors interact to form RISC and execute RNAi in the
cytoplasm (MacRae et al., 2008; Wilson and Doudna, 2013). To
determine whether nuclear RNAi factors also interact, we tested
coimmunoprecipitations of nuclear Ago2, Dicer, TNRC6A, and
TRBP. These coimmunoprecipitations revealed a network of in-
teractions between RNAi factors (Figure 3A).
To further support the observed association of RNAi factors
with Ago2 in nuclei, we generated T47D cells stably expressing
FLAG-HA-tagged Ago2 (FHA-Ago2). Immunoprecipitation of
FHA-Ago2 with FLAG antibody confirmed copurification of
Dicer, TNRC6A, and TRBP (Figure 3B). Coimmunoprecipitation
of Ago2 and Dicer or Ago2 and TNRC6A were also observed in
nuclear extracts treated with RNase A, indicating that the asso-
ciation of RNAi factors was independent of RNA (Figure 3C).
To visualize the association of TNRC6A and Ago2 inside of
cell nuclei, we performed immunofluorescence microscopy.
These experiments revealed colocalization of Ago2 and TNRC6A
staining within HeLa nuclei (Figures 3D and S3). Colocalization of
Ago2 and TNRC6A is consistent with the suggestion from our
coimmunoprecipitation results that nuclear RNAi factors can
form complexes.
To further characterize nuclear complexes containing RNAi
factors, we separated nuclear extracts by size and charge.
Fractionation by size-exclusion chromatography revealed high
molecular weight complexes containing all four RNAi factors
(Figure 3E). To test the involvement of RNA in complex formation,
we treated extracts with RNase A and observed that RNA was
not required. When high molecular weight fractions containing
RNAi factors were further separated by anion-exchange chro-
matography, RNAi factors continued to coelute (Figure 3F)
indicating that the complexes were sufficiently stable to survive
tandem purification schemes. Taken together, these results
demonstrate that nuclear RNAi factors can form stable multipro-
tein RISC-like complexes.
To compare nuclear and cytoplasmic RNAi protein com-
plexes, we performed similar size-exclusion chromatography
with cytoplasmic extract (Figure 3G). The retention time of
Ago2, Dicer, and TNRC6A was similar in cytoplasmic fractions
compared to the nuclear fraction. TRBP, however, eluted later
regardless of the presence or absence of RNase A. As an alter-
nate test for the stability of complexes containing RNAi factors,
we fractionated nuclear and cytoplasmic extracts by adding
increasing amounts of ammonium sulfate. Although all four
RNAi factors precipitated from nuclear extract at 20% ammo-
nium sulfate, a 40% concentration was required for precipitation
from cytoplasmic extract (Figure 3H). These results from(E) Quantification of RNAi factors fromwestern blots of HeLa, T47D, fibroblast,
and A549 cells shown in (D). Error bar is ±SEM.
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Figure 3. RNAi Factors Associate in Multiprotein Complexes in the Nucleus
(A) Coimmunoprecipitation (coIP) of endogenous RNAi factor from HeLa nuclear extract. The antibodies used for the western blot detection are noted to the right,
whereas the antibodies used for immunoprecipitations are on top.
(B) CoIP of RNAi factors from T47D cells expressing FLAG-HA-tagged Ago2 (FHA-A2). HeLa nuclear extract serves as a negative control. Input is extract prior to
immunoprecipitation.
(C) CoIP of Ago2 with Dicer or TNRC6A from T47D nuclear extracts treated with RNase A.
(D) Immunofluorescence of Ago2 and TNRC6A in HeLa cells indicates overlap and colocalization of immunostaining. z stacks (3 mm thickness taken in 0.1 mm
slices) are projected in 3D. The colocalization channel was generated in Imaris (Bitplane). Scale bar represents 5 mm.
(E)Western analysis of fractions from separation of HeLa cell nuclear extract by size exclusion. Extracts were prepared either with our without treatment by RNase
A. Western blot antibodies are shown to the right. Sample fractions are below. Histone H3 is marker for high molecular weight chromatin.
(F) Western analysis of fractions after anion-exchange chromatography of nuclear extract Fraction C from Figure 5E. FT, column flowthrough.
(G) Western analysis of fractions HeLa cytoplasmic extract after size-exclusion chromatography. Extracts were prepared either with our without treatment with
RNase A.
(H) Effect of ammonium sulfate precipitation of RNAi factors from T47D nuclear or cytoplasmic extracts. Western blot antibodies are shown to the right and
ammonium sulfate concentrations (% saturation) are shown above.fractionation by either chromatography or precipitation reveal
the formation of RISC-like complexes, but also suggest that
the exact composition of complexes in the nucleus and the
stability of their association differs from that observed in the
cytoplasm.
RNAi Is Active in the Nucleus
After demonstrating that RNAi factors were present in human
cell nuclei, we investigated whether they could also direct
silencing of nuclear RNA substrates. We examined the
silencing within cytoplasmic, nucleoplasmic, and chromatin-
associated cell fractions. Our target RNAs were Malat1 and
Neat1, long noncoding RNAs (lncRNAs) primarily associated
with chromatin (Figure 4A) (Dodd et al., 2013). For comparison,
we also targeted ribosomal protein L30 (RPL30) and peptidyl-
prolyl isomerase A (PPIA) mRNAs, which are primarily
cytoplasmic.214 Cell Reports 6, 211–221, January 16, 2014 ª2014 The AuthorsWe treated cells with siRNAs targeting each RNA transcript,
fractionated the cells, and then used quantitative PCR (qPCR)
tomeasure RNA levels. As typically observed with siRNAs, levels
of all four RNA transcripts were reduced in the cytoplasmic
fraction (Figure 4B).We observed a similar reduction of transcript
levels in nucleoplasmic and chromatin fractions, consistent with
RNAi activity in nuclei (Figure 4B).
Cleavage at a predicted location is a diagnostic for substrate
processing by Ago2. Therefore, we used 50 rapid amplification
of cDNA ends (50 RACE) to further test whether silencing of
RNA in the nucleoplasm and on chromatin was due to Ago2-
mediated cleavage.We isolated RACEproducts and sequencing
revealed that site-specific cleavage had occurred at the pre-
dicted phosphodiester bond in all cellular fractions for Malat1
(Figures 4C, S4A, and S4B). Identification of the predicted
RACE products associated with chromatin and in nucleoplasm
is additional evidence for nuclear RNAi activity.
Figure 4. RNAi Is Active in the Human Cell
Nucleus
(A) Quantification RNA distribution in HeLa sub-
cellular fractions by qPCR. Error bar is ±SEM.
(B) Quantification by qPCR of siRNA-mediated
lncRNA and mRNA knockdown in HeLa subcellu-
lar fractions. Error bar is ±SEM
(C) 50 RACE to detect siRNA-mediated Ago2
cleavage of Malat1 in chromatin-associated
RNA fractions. Arrow indicates specific cleavage
product.
(D) Cleavage of a 50-radiolabeled luciferase RNA
substrate by Ago2 isolated from cytoplasmic or
nuclear fractions. T1, RNase T1 cleavage; OH,
alkaline hydrolysis; (+) CTRL, synthetic cleavage
product. The region overlapped by the siRNA is
noted.
(E) FISH showing that Malat1 speckles in HeLa
cells are lost upon treatment with siMalat1 siRNA.
z stacks are 5 mm thickness. siLuc, mock treat-
ment. Scale bar represents 5 mm.To further investigate the potential for nuclear Ago2 to cleave
RNA substrates, we set up an in vitro cleavage assay using Ago2
from either cytoplasmic or nuclear fractions and a radiolabeled
RNA substrate derived from luciferase (Luc) mRNA (Elbashir
et al., 2001). Cells were transfected with a duplex RNA (siLuc)
complementary to the Luc RNA substrate or a duplex RNA con-
taining two central mismatches (siLuc_mm). Central mismatches
are known to disrupt slicer activity (Wang et al., 2008). Ago2 was
then immunoprecipitated from either the cytoplasmic or nuclear
fractions and incubated with the radiolabeled target RNA sub-
strate. Reactions were then resolved on denaturing polyacryl-
amide gels to visualize cleavage products.
Ago2 immunoprecipitated from both cytoplasmic and nuclear
extracts of cells treated with siLuc caused sequence-specificCell Reports 6, 211–221cleavage of the Luc substrate (Figure 4D,
lanes 6 and 9). In contrast, Ago2 from
cytoplasmic and nuclear extracts of cells
treated with siLuc_mm did not support
cleavage (Figure 4D, lanes 7 and 10).
A lack of cleavage for siLuc_mm is ex-
pected based on the known slicer mech-
anism of Ago2, which requires perfect
complementarity at the targeted bond
(Wang et al., 2008). These results demon-
strate sequence-specific slicer activity for
nuclear Ago2.
To visualize RNAi-mediated activity
inside cell nuclei, we targeted Malat1
RNA with a siRNA (siMalat1) and per-
formed fluorescence in situ hybridization
(FISH). FISH prior to siMalat1 treatment
revealed distinct nuclear speckles. Upon
treatment with siMalat1, the Malat1
speckles disappeared. In contrast to the
disappearance of speckles after treat-
ment with siMalat1, a siRNA with no
cellular target (siLuc) had no effect(Figures 4E, S4C, and S4D). Taken together, several lines of
evidence are consistent with RNAi slicer activity in cell nuclei,
including (1) siRNA-mediated reduction in the levels of nuclear
RNA targets, (2) site-specific cleavage of nuclear RNA targets
at a position diagnostic for RNAi, (3) cleavage of target RNA by
Ago 2 isolated from nuclear extract, and (4) visualization of
reduced target RNA within cell nuclei.
miRNAs in Cell Nuclei
We evaluated the localization of miRNAs within cell nuclei and
their association with Ago2. Sequencing of small RNAs revealed
that out of 456 miRNA species identified in the whole cell, 346 of
them also exist in cell nuclei, suggesting that roughly 75% of
miRNAs in the cytoplasm are shuttled into the cell nucleus, January 16, 2014 ª2014 The Authors 215
Figure 5. miRNAs Are in the Nucleus and Associate with Ago2
(A) Distribution of miRNAs by single molecule small RNA sequencing in nuclei versus whole cell.
(B and C) Relative abundance of top 20 miRNAs in whole-cell versus nuclear fractions.
(D) Top 20 miRNAs bound to nuclear Ago2 identified by immunoprecipitation and single molecule small RNA sequencing. Results are compared to a negative
control from immunoprecipitation using a nonspecific antibody (IgG).
(E) Detection of processing products from cytoplasmic and nuclear Dicer. RNAmolecular weight ladder is shown to the left (lane 1). Arrow indicates specific Dicer
processing product band.(Figure 5A). The identities of many of the top 18 ranked miRNAs,
based on the number of obtained sequencing reads, were the
same between nuclei and whole cell (Figures 5B and 5C), indi-
cating a similar distribution of abundant miRNA species in the
cytoplasm and the nucleus.
We then examined the association of miRNAs with Ago2 in cell
nuclei. Ago2 was immunoprecipitated from nuclear extract using
a nonspecific mouse immunoglobulin G (IgG) as a negative
control. Bound small RNAs were isolated and sequenced on a
Helicos single molecule sequencer using direct RNA sequencing
mode. In this mode, the steps of making complementary DNA
and PCR amplification are avoided so that potential sequencing
biases are eliminated. The number of sequencing reads better
represents the original miRNA expression level. We prepared216 Cell Reports 6, 211–221, January 16, 2014 ª2014 The Authorstwo biological replicates and averaged the sequencing read
number for each small RNA. Single molecule sequencing
revealed substantial binding of numerous miRNAs to nuclear
Ago2 (Figure 5D).
To further examine the potential for miRNA pathways to
operate in the nucleus, we tested the ability of Dicer, the enzyme
that processes pre-miRNA precursors, to generate mature
miRNAs in nuclear or cytoplasmic extracts. We performed an
in vitro processing assay in which we immunoprecipitated Dicer
from cytoplasmic or nuclear extracts, mixed it with radiolabeled
pre-miR-19a, and analyzed cleavage products by denaturing
polyacrylamide gel electrophoresis. We observed the expected
23 nucleotide product for both nuclear- and cytoplasmic-derived
Dicer (Figure 5E). These results suggest that Dicer can process
Figure 6. Duplex Small RNA Loading Is Deficient and RISC Loading Factors Are Absent in Nuclear Extracts
(A) Cleavage of a 50-radiolabeled luciferase RNA substrate by Ago2 isolated from cytoplasmic or nuclear fractions treated as shown above the gel. T1, RNase T1
cleavage; OH, alkaline hydrolysis; (+) CTRL, synthetic cleavage product.
(B) Coprecipitation of radiolabeled duplex siLuc or radiolabeled single-strand siLuc guide RNA incubated with Ago2 after immunoprecipitation from nuclear or
cytoplasmic extracts.
(C and D) In vitro assay for Ago2 duplex siRNA loading in extracts. Radiolabeled siRNA is added to extracts from human cell lines, Ago2 immunoprecipitated with
Ago2 or FLAG antibody, and copurified RNA resolved on a denaturing polyacrylamide gel. FHA-A2-c1 and FHA-A2-c3 are two different T47D clonal cell lines
stably expressing FLAG-HA-tagged Ago2.
(E) Radiolabeled siLuc was used in the same assay shown in (C) and (D), but copurified RNA was resolved on a nondenaturing polyacrylamide gel. Immuno-
precipitation wash conditions and shown below the gel and the copurified duplex or single-strand RNAs indicated to the right.
(F) Radiolabeled miR-19a or siLuc were used in the same assay shown in (C) and (D). Mismatch positions relative to the 50 end of the guide strand are indicated
above the gel.
(G) Western blot of RISC loading and maturation factors and subcellular markers from cytoplasmic and nuclear fractions.pre-miRNAs in the nucleus and is consistent with the potential
for nuclear regulation and production of small RNAs.
Small Duplex RNA Loading of Ago2 Is Deficient in
Nuclear Extract
Observed differences in fractionation of nuclear versus cyto-
plasmic RNAi factor complexes (Figure 3) suggested that other
differences between cytoplasmic and nuclear RISC might exist.
To extend our analysis, we tested whether there might be differ-
ences in small RNA loading between the nucleus and cytoplasm.
When examining Ago2 slicer activity in vitro (Figure 4D), our ex-
tracts were initially prepared from cells that were transfected with
siRNA. This protocol requires the RNA to pass through the cyto-
plasm before entering the nucleus, and therefore loading might
occur in the cytoplasm. Subsequent nuclear import of loaded
Ago2 complexes might then account for the slicer activityCobserved in the nucleus (Ohrt et al., 2008; Weinmann et al.,
2009). To determine where loading was occurring, we added
small RNAs directly to nuclear extracts prepared from untreated
cells andsubsequently performed in vitroassays for slicer activity.
As we had observed previously, when Ago2 is isolated from
extracts of cells transfected with siLuc, Ago2 from both the
cytoplasm and nucleus can catalyze cleavage of the Luc
substrate RNA (Figure 6A, lanes 8 and 12). By contrast, extracts
fromuntransfectedcellswheredouble-strandedsiLucwasadded
after extractpreparation revealed that cytoplasmicAgo2wasable
tocatalyzecleavagebut thatnuclearAgo2was inactive (Figure6A,
lanes 6 and 10). These data are consistent with nuclear slicer
activity and replicateourprevious findings (Figure 4), but alsosug-
gest a deficiency in Ago2 loading in nuclear extracts.
We further examined the loading of single-stranded guide
RNA alone. Single-stranded RNAs are usually rapidly degradedell Reports 6, 211–221, January 16, 2014 ª2014 The Authors 217
in cell extracts, precluding efficient loading. Nevertheless we
found that addition of the single-stranded siLuc guide strand
conferred low but similar levels of cleavage for both cytoplasmic
and nuclear Ago2 (Figure 6A, lanes 7 and 11).
RNA single strands can be directly bound by Ago2 without
the need for additional factors (Rivas et al., 2005). As a control
to ensure that nuclear Ago2 was accessible for loading, we
immunoprecipitated Ago2 and then incubated it with a radio-
labeled single-strand siLuc guide RNA. We found that both
cytoplasmic and nuclear Ago2 were able to bind the single-
stranded guide (Figures 6B and S5A). Taken together, our
observations that Ago2 from nuclear extract can (1) direct
cleavage of an RNA target after mixing with single-stranded
but not duplex RNA and (2) bind single-strand RNA are
consistent with the loading of duplex RNA being deficient in
cell nuclei.
Because duplex RNAs are susceptible to degradation by
nucleases (Braasch et al., 2003), we considered the possibility
that nuclear extracts could harbor a nuclease activity that might
interfere with loading. When duplex RNA was incubated with
either nuclear or cytoplasmic extracts, we observed similar
levels of degradation over time (Figure S5B), suggesting that
nuclease activity cannot explain our findings.
To more directly investigate Ago2 loading with duplex
small RNA, we developed an in vitro loading assay. We added
duplex siLuc with a radiolabeled guide strand to either nuclear
or cytoplasmic extracts. When Ago2 was immunoprecipitated
with antibodies against either endogenous or FLAG-tagged
Ago2, we observed copurification of radiolabeled siLuc guide
strand with cytoplasmic, but not nuclear, Ago2 (Figures 6C and
6D). A lack of nuclear loading was still observed when both siLuc
strands were radiolabeled, ruling out a potential passenger
strand loading bias in the nucleus (Figure S5C). We also
confirmed that similar amounts of Ago2 were immunoprecipi-
tated from both extracts in our experiments (Figure S5D).
Nuclear extracts are unlikely to support efficient ATP regenera-
tion for some RNAi processes (Klouwen and Appelman, 1967;
Zamore et al., 2000). Because RISC loading has been reported
to require ATP (Iwasaki et al., 2010), we used phosphocreatine
and creatine kinase (Calhoun and Swartz, 2007) to regenerate
ATP. We observed no change in loading in the nuclear extract
(Figure S5E), excluding insufficient ATP as a possible explana-
tion for the duplex loading deficiency.
Small duplex RNA loading involves an initial step when
the duplex first binds to RISC and an unwinding step when the
passenger strand is removed (Iwasaki et al., 2010; Matranga
et al., 2005; Ye et al., 2011). To determine the limiting step in
nuclear loading, we performed the in vitro Ago2 loading
assay under conditions that would discriminate between duplex
siRNA or single-strand guide RNA bound to Ago2. Immuno-
precipitations were washed with the standard high-salt (0.5 M
NaCl) buffer or with a low-salt (0.15 M NaCl) buffer to potentially
preserve formation of unstable Ago2-RNA complexes. When
RNA isolated from Ago2 immunoprecipitations was resolved
by native gel electrophoresis, both duplex and single-stranded
RNAs were bound to cytoplasmic Ago2, indicating formation
of both complexes during loading (Figure 6E). In contrast,
neither complex was formed during loading in nuclear extracts.218 Cell Reports 6, 211–221, January 16, 2014 ª2014 The AuthorsThis result demonstrates that the initial step of duplex RNA
loading is deficient in nuclear extracts.
Our observation of miRNAs and Dicer activity in cell nuclei
(Figure 5) led us to examine loading of miRNAs. We tested
loading of a miR-19a duplex miRNA and duplex RNAs based
on siLuc that contained central or terminal mismatches. Like fully
complementary RNAs, we observed that mismatched duplexes
were loaded in cytoplasmic extract but were not loaded in
nuclear extract (Figure 6F). These results suggest that duplex
miRNAs may also be differentially loaded between the nucleus
and the cytoplasm.
Because several proteins are implicated in Ago2 loading and
RISC maturation (Iwasaki et al., 2010; Pare et al., 2013; Ye
et al., 2011), we performed western blot to detect their presence
in isolated nuclei. Surprisingly, these loading factors, Hsp90,
Translin, TRAX, Aha1, FKBP4, Cdc37 and p23, were all exclu-
sively cytoplasmic (Figure 6G). The only exception was Hsc70,
which was found in both the nucleus and the cytoplasm. These
results are consistent with a loading restriction to the cytoplasm
and suggest that programming of RNAi via Ago loading is regu-
lated by exclusion of critical loading factors from the nucleus.
DISCUSSION
There has been conflicting evidence over the presence and
activity of canonical RNAi factors in mammalian somatic cell
nuclei. The biological significance of the nucleus in the regulation
of RNAi pathways has also been unclear. This uncertainty has
obscured the potential for small RNAs to participate in the regu-
lation of nuclear processes. In this study, we used multiple
methods to test whether RNAi factors and RNAi activity could
be detected in mammalian cell nuclei. We employed protocols
for purifying nuclei that are free of ER protein contamination for
in vitro analyses and methods for visualizing RNAi factors and
RNAi activity in cell nuclei.
Our complementary experimental approaches support the
existence of nuclear RNAi but also indicate that it differs from
cytoplasmic RNAi. We find that (1) Ago2, the catalytic engine
of RNAi, and the RNAi factors Dicer, TRBP, and TNRC6A are
all present in human cell nuclei; (2) these nuclear-localized
RNAi factors can associate in stable multiprotein complexes;
(3) small RNAs can reduce levels of nuclear-localized RNA tar-
gets through site-specific cleavage; (4) Ago2 and Dicer isolated
from nuclei exhibit catalytic activity; (5) the effects of RNAi activ-
ity can be visualized inside of human cell nuclei by FISH; (6)
endogenous miRNAs are bound to nuclear Ago2 and miRNA
pathway components are in the nucleus; (7) programming of
RNAi through Ago2 loading with duplex small RNAs is not
observed in nuclear extracts; and (8) necessary RISC loading
and maturation factors are absent from the nucleus.
A previous study from Meister and colleagues reported on
the presence and complex formation of EGFP-tagged Ago2 in
human cell nuclei using fluorescence correlation and cross-
correlation spectroscopy (Ohrt et al., 2008). Consistent with their
results, we also observed Ago2 in the nucleus. However, they
found that nuclear EGFP-Ago2 did not appear to associate
with large complexes. These differences may be accounted for
by our focus on endogenous Ago2 and by variations in
fractionation techniques. Based on spectroscopy data, Ohrt
et al. (2008) also proposed that Ago2 is loaded in the cytoplasm
and imported into the nucleus. Our data support this hypothesis
with biochemical evidence and provide a potential explanation
by observing a nuclear absence of the known RISC loading fac-
tors. The exclusion of RNAi programming from the nucleus has
important implications for RNAi because small RNAs that are pri-
marily nuclear may be loaded inefficiently or not at all. This par-
titioning of RISC loading may have evolved to regulate the
involvement of nuclear small RNA in RNAi-mediated processes.
The activity and regulation of RNAi factors in mammalian cell
nuclei might have multiple impacts on gene regulation. Small
RNAs could potentially guide RNAi factors like Argonaute to
nuclear RNA species, such as noncoding RNAs at gene pro-
moters to affect transcription or intronic RNA to alter splicing.
Nuclear RNAi-like pathways exist in various eukaryotic organ-
isms like plants, flies, worms, fungi, and ciliated protozoa (Castel
and Martienssen, 2013; Gagnon and Corey, 2012). These path-
ways have been characterized to regulate processes like nuclear
gene expression, epigenetic states, and genome maintenance
(Malone and Hannon, 2009). The demonstrated presence and
activity of canonical RNAi factors in mammalian cell nuclei sug-
gest that similar pathways may exist in humans.
We have recently reported a role for Ago2 and TNRC6A in
endogenous control of the inflammatory pathway genes cyclo-
oxygenase 2 (COX-2) and phospholipase 2G 4A (PLA2G4A)
by miR-589 miRNA (Matsui et al., 2013). COX-2 and PLA2G4A
are adjacent geneswhose promoters are linked by chromosomal
looping. miR-589 is expressed in A549 lung cancer cells and has
two seed sequence target sites at the COX-2 promoter. Elevated
levels of miR-589 lead to increased expression of both COX-2
and PLA2G4A. Ago2 and TNRC6A are recruited by miR-589 to
a sense transcript that overlaps the COX-2 promoter. When
Ago2 or TNRC6A levels are depleted, the activation of COX-2
and PLA2G4A by miR-589 is reversed. These results provide
an experimental demonstration that nuclear RNAi factors can
play a role in regulating a physiologically important regulatory
pathway.
Mammalian RNAi has typically been assumed to localize to the
cytoplasm, limiting the vision of researchers investigating the
regulation of gene expression. Clarity about RNAi factors and
their activity in the nucleus widens investigation of RNAi beyond
traditional targets in the cytoplasm to targets in the nucleus that
may regulate processes like transcription or splicing. Although
much remains to be learned about nuclear RNAi, such control
in the nucleus would add a new layer of gene regulation and offer
new options for RNAi-based therapeutics.
EXPERIMENTAL PROCEDURES
Tissue Culture and siRNA Transfection
HeLa, T47D, fibroblast, and A549 cells were cultured in their standardmedia at
37C in 5% CO2. Lipofectamine RNAiMAX (Invitrogen) was used to deliver
siRNAs into cells following the manufacturer’s recommended protocol.
Sequences of siRNAs used are listed in Table S1.
Nuclear and Cytoplasmic Cell Fractions
Cells were lysed in hypotonic lysis buffer (HLB) (10 mM Tris-HCl [pH 7.5],
10 mM NaCl, 3 mM MgCl2, 0.3% NP-40) supplemented with 1% Protease In-Chibitor (PI), 1 mM NaF, and 1 mM Na3VO4. Cells were spun and supernatant
kept as cytoplasmic extract after addition of NaCl to 0.15 M and glycerol to
10%. Pelleted nuclei were washed three times with HLB. To make nuclear
extract, nuclei were resuspended in nuclear lysis buffer (same as HLB but con-
taining 0.15 M NaCl and 10% glycerol) also supplemented with PI, NaF, and
Na3VO4. Nuclei were sonicated and supernatant kept as nuclear extract.
Coimmunoprecipitation
Protein G Plus/Protein A resin (Calbiochem), antibody and precleared nuclear
extract were mixed at 4C for 2–3 hr. When indicated, 20 mg RNase A was
added before incubation. Resin was washed with IP wash buffer (20 mM
Tris-HCl [pH 7.5], 0.4 M NaCl, 2 mM MgCl2, 0.05% NP-40, 0.025% SDS)
and copurified proteins eluted with SDS-PAGE loading buffer. Specific pro-
teins were detected by western blot.
Chromatographic Separation and Ammonium Sulfate Cuts of Cell
Extracts
For size-exclusion chromatography, extracts were either treated with RNase A
or SUPERase-In (Ambion), filtered, injected onto a Superdex 200HiLoad 16/60
column (Amersham Pharmacia) preequilibrated with FPLC buffer (20 mM Tris-
HCl [pH 7.5], 150 mM NaCl, 3 mM MgCl2, 5% glycerol), and separated by
FPLC. Eluted fractions were assayed by western blot. For subsequent frac-
tionation by anion exchange, size-exclusion fractions were concentrated
and injected onto a Mono-Q FPLC column (Amersham Pharmacia) equili-
brated with FPLC buffer at 0.1 M NaCl. Elution was performed by linear
gradient from 0.1 to 1 M NaCl. For ammonium sulfate precipitation, saturated
ammonium sulfate solution was added to cell extracts at the indicated final
percentages, incubated on ice for 15 min, spun down at 18,000 3 g at room
temperature, and pelleted precipitate resuspended in SDS loading buffer. Su-
pernatant was kept and additional ammonium sulfate added for the next cut.
Fractions were analyzed by western blot.
Analysis of siRNA-Mediated RNA Knockdown in Cellular
Compartments
HeLa cells were transfected with 25 nM siRNA and then harvested 72 hr later.
Cells were counted and fractionated similarly to above. However, instead of
sonicating, nuclei were lysed with modified Wuarin-Schibler buffer (MWS)
(10 mM Tris-HCl [pH 7.0], 4 mM EDTA, 0.3 M NaCl, 1 M urea, 1% NP-40)
(Wuarin and Schibler, 1994). Supernatant was kept as nucleoplasmic fraction
and chromatin washed. RNA was isolated from cytoplasmic and nucleo-
plasmic fractions by precipitation and Trizol extraction. RNA was isolated
from chromatin by Trizol extraction.
In Vitro Ago2 Cleavage Assay
HeLa cells were either untreated or transfected with 25 nM siLuc or siLuc_mm
(see Table S1) and then harvested 36 hr later, and nuclear and cytoplasmic
extracts were prepared. When indicated, siRNA or single-strand guide RNA
was incubated with extract from untreated cells for 1 hr at room temperature
with rotation. Ago2 was immunoprecipitated using Ago2 antibody (Abcam,
ab57113), Protein G Plus/Protein A agarose (Calbiochem), and 200 ml extract
at room temperature rotation for 1 hr. Resin was washed with IP wash buffer
(IPWB) (20 mM Tris-HCl [pH 7.5], 4 mM MgCl2, 0.5 M NaCl, 0.05% NP-40)
and then mixed with 50 radiolabeled synthetic target RNA substrate in 1 3
RNAi buffer (20 mM Tris-HCl [pH 7.5], 4 mM MgCl2, 0.5 mM DTT, 80 mM
NaCl, 20 mM KCl, 0.5 mM EDTA) supplemented with 1 mg/ml yeast tRNA,
20 units SUPERase-In (Ambion), and 0.5 mM ATP. Reactions were incubated
at 30C for 1.5 hr with periodic mixing, and then target RNA and cleavage
products were phenol extracted. Extracted RNAwas resolved on a 15%dena-
turing polyacrylamide sequencing gel. The gel was dried and exposed to a
phosphorimager screen overnight to visualize radioactive bands.
Immunofluorescence and Colocalization Analysis
Immunofluorescence was performed similarly to that previously described
(Ohrt et al., 2012; Spector, 2011) with modifications. Briefly, cells were grown
on 35 mm dishes with a 14 mm glass bottom. Cells were fixed in 2% formal-
dehyde or 4% paraformaldehyde. Fixed cells were then permeabilized with
0.2% Triton X-100 or 70% ethanol. Cells were incubated in primary antibodyell Reports 6, 211–221, January 16, 2014 ª2014 The Authors 219
in PBS + 1% normal goat serum (NGS), washed, incubated with secondary
antibody + 1% NGS, washed again, and then set in mounting medium with
DAPI and imaged. Cells were imaged by wide-field epifluorescence micro-
scopy and images processed by blind deconvolution with AutoQuant X3
(Media Cybernetics). Alternatively, some samples were imaged by Andor
spin disc confocal microscopy. Colocalization channels were calculated using
Imaris (Bitplane) based on the correlation of the strength of linear relation
between the two channels. Threshold levels for calculation were selected
above background.
Fluorescence in Situ Hybridization
Cells were grown on 35 mm MatTek dishes and transfected with 25 nM siLuc
or siMalat1 as described above. Cells were fixed in ice-cold 4% PFA and per-
meabilized in 70%. From this point forward, the protocol recommended by the
manufacturer of the FISH probes for Malat-1 (Biosearch Technologies, New
Stellaris RNA FISH Probe for Malat-1, SMF-2035-1) was followed. Cells
were set with mounting medium with DAPI and imaged as above for IF.
Small RNA Sequencing
Small RNA sequencing libraries were constructed from either whole-cell RNAs
or nuclear RNAs isolated from T47D cells and sequenced on Illumina Hiseq
2000. The reads were aligned to human genome hg19, UCSC miRNA data-
base, and/or miRBase (mature miRNA).
Ago2-associated miRNA in cell nucleus was isolated by RNA immunopre-
cipitation using a specific Ago2 antibody. Small RNA (<40 nt) including miRNA
was further isolated by gel purification. The small RNA was then subjected to
poly(A) tailing and sequenced on a single-molecule Helicos sequencer with a
Direct RNA Sequencing (DRS) module.
In Vitro Ago2 Small RNA Loading Assay
Duplex siRNA or single-strand guide RNA radiolabeled at the 50 end was incu-
bated with extract supplemented with 1 mM ATP for 1 hr at room temperature
with rotation. Ago2 was immunoprecipitated using Ago2 antibody (Abcam,
ab57113) and Protein G Plus/Protein A agarose (Calbiochem). Resin was
washed with IP wash buffer (IPWB) (20 mM Tris-HCl [pH 7.5], 4 mM MgCl2,
0.5 M NaCl, 0.05% NP-40) and then phenol-chloroform extract to isolate
copurified RNA. Extracted RNA was resolved on a 15% denaturing polyacryl-
amide sequencing gel or a 15% native TBE-buffered polyacrylamide gel. The
gel was dried and exposed to a phosphorimager screen overnight to visualize
radioactive bands.
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